Filtration and processing tech firm Pall Life Sciences’ biopharmaceutical business made the biggest contribution to its revenues revenues in fiscal Q2.
The joint US FDA and EMA active pharmaceutical ingredient (API) manufacturing facility inspection programme has signed up the World Health Organisation as a member.
Frontage Laboratories says it is focussing on improving regulatory and GMP compliance in China after signing a $10m (€7.5m) collaboration with drugs maker Fanghui Pharma.
Freeman Technology says growing Pharma demand for analytical data prompted the formation of US subsidiary and it behind its plans for a new laboratory.
Hospira hopes to ramp up output at its Rocky Mount facility in the second half of 2012 but warned it is “very difficult” to predict the remediation timeline.
Lonza has denied reports it has signed a deal with the South African government to build a $210m (€159m) API plant, saying it is merely “in discussions” over plans.
The Council of Europe (CoE) has launched an online service which will allow patients to check the authenticity of their medication using just a smartphone.
AMRI says the US FDA has no concerns about its sterile fill-finish facility in Burlington, Massachusetts and that the challenge now is to win back customers.
AMRI posted a Q4 loss on lower sales but predicts that contracting revenues and margins will increase in 2012 thanks to cost cutting measures and new contracts
Outsourcing-pharma.com presents a round up the latest developments in the contract manufacturing sector – with news from Cambrex, Florida Biologix, SCM Pharma, Recipharm and OctoPlus.
The Indian Drug Manufacturers Association (IDMA) plans to amp up pharma business in Tamil Nadu by helping more companies meet WHO production standards.
Encap Drug Delivery has won a contract manufacturing deal for a European licensed liquid-filled capsule product after the owner parted from its current CMO.
